Kidney News and Research

RSS

Harmful effects of energy drinks on children

A new study published in the journal Pediatrics on Monday examined the risks of consumption of high-caffeine energy drinks on children and young adults. The study notes that these drinks are linked to an array of serious events like heart palpitations, high blood pressure and even cardiac arrest and death. The risk rises if young adults consuming the drink suffer from chronic diseases or take other medications.

14 Feb 2011

New clinical trial to test surgery specifically for Type 2 diabetes

A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for Type 2 diabetes. The aim of the study is to understand whether surgery can control diabetes, as well or even better than the best medical treatment available today. This is the first study of its kind open to patients who are overweight or mildly obese.

14 Feb 2011

U.S. FDA clears QMS Everolimus Immunoassay to prevent rejection in kidney transplants

The U.S. Food and Drug Administration today announced that it has cleared a test to help manage potential organ rejection in kidney transplant patients. The test, called QMS Everolimus Immunoassay, monitors the blood level of everolimus, a drug that helps prevent rejection in kidney transplants.

14 Feb 2011

New research: LED products actually contain hazardous substances

Those light-emitting diodes marketed as safe, environmentally preferable alternatives to traditional lightbulbs actually contain lead, arsenic and a dozen other potentially hazardous substances, according to newly published research.

13 Feb 2011

Daily diet soda raises stroke risk by 61%: Study

A new study suggests that regular intake of diet soda may be boosting the risk of stroke. Stroke is the third leading killer following heart disease and cancer, in the United States. More than 137,000 people a year die from stroke, according to the American Stroke Association.

13 Feb 2011

AHRQ: $25.3 billion spent for kidney disease treatment every year

Overall, an average of 3.7 million adults in the United States were treated for kidney disease each year between 2003 and 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. Kidney disease can lead to renal failure and may be caused by diabetes, high blood pressure and heart disease.

11 Feb 2011

New tool helps doctors assess likelihood of death from stroke

Researchers at St. Michael's Hospital and the Institute for Clinical and Evaluative Sciences (ICES) in Toronto have developed a new tool that will help doctors predict the probability of death in patients after an ischemic stroke.

11 Feb 2011

New trial tests surgery for Type 2 diabetes

11 Feb 2011

£160,000 award to devise anti-microbial collar to prevent bacterial infections associated with broken bones

Orthopaedic experts at The University of Nottingham are hoping to reduce the rate of infections that often occur in the pinning of broken bones by developing a special collar to counter dangerous microbes.

11 Feb 2011

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 1b clinical study of PRM-151 to explore the safety, tolerability, pharmacokinetics, and phamacodynamics of PRM-151 in the treatment of patients with idiopathic pulmonary fibrosis.

11 Feb 2011

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

11 Feb 2011

Alexion fourth quarter net product sales of Soliris increases to $156.0 million

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.

10 Feb 2011

Americans willing to pay more, but up to a limit, for safer food

Government regulators could more realistically assess the value of improving food safety if they considered the fact that consumers typically want to avoid getting sick - even if it means they have to pay a little extra for safer food, researchers say.

10 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Cardiac enzyme elevations following CABG surgery is associated with worse prognosis

Patients who underwent coronary artery bypass graft surgery and had elevated levels of the cardiac enzymes creatine kinase or troponin in the 24 hours following surgery had an associated intermediate and long-term increased risk of death, according to a study in the February 9 issue of JAMA.

9 Feb 2011

Study finds low awareness about kidney risks posed by diabetes

The first time that many patients realise that diabetes can affect their kidneys is when they are referred to renal services, according to a multi-cultural study in the March issue of the Journal of Renal Care.

9 Feb 2011

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.

9 Feb 2011

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track review status for Vascugel® for the prevention of hemodialysis access failure in patients with end stage renal disease (ESRD).

9 Feb 2011

Abacus introduces new e-blood pressure control system for hospitals

Abacus Health Solutions has developed a new e-health enabled blood pressure monitoring and feedback system to improve health outcomes for hospital specialty clinics.

8 Feb 2011

Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

JumpStart Ventures, the non-profit that invests in and partners with innovative, early-stage companies in Northeast Ohio, and Cleveland Clinic, announced a combined investment commitment of $500,000 in SironRX Therapeutics, Inc. The Cleveland-based company is developing a topical therapy to enhance healing of and decrease scar formation in wounds.

8 Feb 2011